Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 patients: phase 2b COMMAND-1 SVR12 results - Hezode, C; Hirschfield, G M; Ghesquiere, W; Sievert, W
Paper presented at: AASLD The Liver Meeting; November 9–13, 2012; Boston, MA